ArticleCancer science2018

Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands.

Takashi Akazawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.